GuidelineEuropean urology2019
Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.
Guideline in European urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis.World journal of urology · 2026Pooled it
- 10 mm (PI-RADS v2.1) versus 15 mm (PI-RADS v1.0) tumor capsule contact length in predicting extracapsular extension in prostate cancer: Meta-analysis and systematic review.Abdominal radiology (New York) · 2025Pooled it
- Comparison of diagnostic performance and inter-reader agreement between PI-RADS v2.1 and PI-RADS v2: systematic review and meta-analysis.The British journal of radiology · 2022Pooled it
- Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Predictive Value of Multiparametric Magnetic Resonance Imaging (T2-weighted Imaging and Apparent Diffusion Coefficient) for Pathological Grading of Prostate Cancer: a Meta-Analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Artificial intelligence-assisted reading of non-contrast prostate MRI: application and concordance with expert interpretation in a screening population within the PROSA trial.European radiology · 2026Trial
- Transrectal Ultrasound-Guided Prostate Biopsy with and without PSMA-PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer.BioMed research international · 2023Trial
- Full-Field Optical Coherence Tomography for Immediate Analysis of Prostate Biopsy Cores: A New Step toward Real-Time Cancer Diagnosis.Annals of surgical oncology · 2026Article
- Improving the diagnostic efficacy of MR cytometry in prostate cancer imaging.Abdominal radiology (New York) · 2026Article
- The value of multiparametric magnetic resonance imaging in the prognostic judgment of prostate cancer.Scientific reports · 2026Article
- A Nonlinear Single Channel Gradient Insert for Prostate Diffusion Imaging.Magnetic resonance in medicine · 2026Article
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.JAMA network open · 2026Article
- Transition from Transrectal Systematic to Transperineal Lesion-Focused Prostate Biopsy: A Real-World Comparative Analysis.Cancers · 2026Article
- Adaptive ensemble learning for prostate cancer classification on multi-modal MRI: reducing unnecessary biopsies.BMC medical imaging · 2026Article
- The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy.International urology and nephrology · 2026Article
- Fast and High-Resolution luminal water imaging for prostate cancer diagnosis.Magnetic resonance in medicine · 2025Article
- Artificial Intelligence in Prostate MRI: Current Evidence and Clinical Translation Challenges-A Narrative Review.Journal of imaging · 2025Review
- Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study.Military Medical Research · 2025Article
- Biopsy strategies in the era of mpMRI: a comprehensive review.Prostate cancer and prostatic diseases · 2025Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
contextThe Prostate Imaging-Reporting and Data System (PI-RADS) v2 analysis system for multiparametric magnetic resonance imaging (mpMRI) detection of prostate cancer (PCa) is based on PI-RADS v1, accumulated scientific evidence, and expert consensus opinion.
objectiveTo summarize the accuracy, strengths and weaknesses of PI-RADS v2, discuss pathway implications of its use and outline opportunities for improvements and future developments. EVIDENCE ACQUISITION: For this consensus expert opinion from the PI-RADS steering committee, clinical studies, systematic reviews, and professional guidelines for mpMRI PCa detection were evaluated. We focused on the performance characteristics of PI-RADS v2, comparing data to systems based on clinicoradiologic Likert scales and non-PI-RADS v2 imaging only. Evidence selections were based on high-quality, prospective, histologically verified data, with minimal patient selection and verifications biases. EVIDENCE SYNTHESIS: It has been shown that the test performance of PI-RADS v2 in research and clinical practice retains higher accuracy over systematic transrectal ultrasound (TRUS) biopsies for PCa diagnosis. PI-RADS v2 fails to detect all cancers but does detect the majority of tumors capable of causing patient harm, which should not be missed. Test performance depends on the definition and prevalence of clinically significant disease. Good performance can be attained in practice when the quality of the diagnostic process can be assured, together with joint working of robustly trained radiologists and urologists, conducting biopsy procedures within multidisciplinary teams.
conclusionsIt has been shown that the test performance of PI-RADS v2 in research and clinical practice is improved, retaining higher accuracy over systematic TRUS biopsies for PCa diagnosis. PATIENT SUMMARY: Multiparametric magnetic resonance imaging (MRI) and MRI-directed biopsies using the Prostate Imaging-Reporting and Data System improves the detection of prostate cancers likely to cause harm, and at the same time decreases the detection of disease that does not lead to harms if left untreated. The keys to success are high-quality imaging, reporting, and biopsies by radiologists and urologists working together in multidisciplinary teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.